STOCK TITAN
  1. Home
  2. News
  3. AVIR

Atea Pharmaceuticals Inc - AVIR STOCK NEWS

IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19
clinical trial covid-19
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update
earnings
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on March 30, 2021
conferences earnings
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Presents Favorable Phase 1 Results for AT-527 at 28th Annual Conference on Retroviruses and Opportunistic Infections
clinical trial
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Announces Chugai In-License of AT-527 from Roche for the Treatment of COVID-19 in Japan
covid-19
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Announces Publication of Preclinical Data Highlighting Potent Activity of AT-527 Against SARS-CoV-2
clinical trial
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient Setting
clinical trial
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Expands Senior Management Team with Key Additions in Regulatory Affairs and Investor Relations and Corporate Communications
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference
conferences
IMPACT
SENTIMENT
AVIR : Nasdaq
Atea Pharmaceuticals Added to Russell 2000 Index
Stock AVIR logo
Atea Pharmaceuticals Inc

Nasdaq:AVIR

AVIR Rankings

#4189 Ranked by Market Cap
#4631 Ranked by Stock Gains
N/A Ranked by Dividends

AVIR Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Boston

About AVIR

atea pharmaceuticals, inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. the company's lead product candidate is at-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. it also develops at-787 which is under phase 2 clinical for the treatment of hepatitis c virus; at-752 which is under phase 2 clinical trial for the treatment of dengue; and at-889, at-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. the company was incorporated in 2012 and is based in boston, massachusetts.